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Percutaneous Left Atrial Appendage Closure May be 
a Therapeutic Alternative in Patients with Atrial 
Fibrillation (AF) and Absolute Contraindications to 
Anticoagulation Therapy 
Left atrial appendage closure (LAAC) with the 
AMPLATZER Cardiac Plug (ACP) was successfully 
performed in 51 of 52 (98%) patients (aged 74+8 years) 
with AF and absolute contraindications to anticoagulation 
therapy. Most patients received dual-antiplatelet therapy 
after the procedure for 1-3 months and single antiplatelet 
therapy thereafter. Main complications were device 
embolization (1.9%) and pericardial effusion (1.9%), with 
no cases of periprocedural stroke. At follow-up (20+5 
months), death rate was 5.8%, stroke 1.9%, systemic 
embolism 0%, pericardial effusion 1.9%, and major 
bleeding 1.9%. The presence of mild peridevice leak was 
observed in 16.2% of patients at the 6-month follow-up as 
evaluated by transesophageal echo. There were no cases 
of device thrombosis. The authors concluded that in 
patients with nonvalvular AF at high risk of 
cardioembolic events and absolute contraindications to 
anticoagulation, LAAC using the ACP device followed 
by dual-/single-antiplatelet therapy was associated with a 
low rate of embolic and bleeding events and no device 
thrombosis at short and midterm follow-up (Urena M et 
al, J Am Coll Cardiol 2013;62:96–102). 
 
Preliminary Favorable Experience With Percutaneous 
Left Atrial Appendage Suture Ligation Using the 
LARIAT Device in Patients With Atrial Fibrillation 
Percutaneous ligation of the left atrial appendage 
(LAA) with the LARIAT device (a snare with a pre-tied 
suture guided epicardially over the LAA) was success-
fully performed in 85 of 89 (96%) patients with complete 
closure achieved in 81 patients, while 4 had a <2-3-mm 
residual LAA leak. There were 3 complications (during 
pericardial access, n=2; & transseptal catheterization, 
n=1). Adverse events included severe pericarditis post-
operatively (n=2), late pericardial effusion (n=1), sudden 
death (n=2), & late strokes (n=2). At 1 (81 of 85) & 3 
months (77 of 81) post-ligation, 95% of the patients had 
complete LAA closure by transesophageal echo (TEE). 
Of the 65 patients undergoing 1-year TEE, there was 98% 
complete LAA closure, including patients with previous 
leaks. The authors concluded that LAA closure with the 
LARIAT device can be performed effectively with 
acceptably low complication rate (Bartus et al, J Am Coll 
Cardiol 2013;62:108–118).  
 
NEXT Trial: Low Rate of Restenosis and Stent 
Thrombosis With the Biodegradable Polymer 
Biolimus-Eluting Stent  
A biodegradable polymer biolimus-eluting stent-BES 
(Nobori) (n=1617) was compared with a durable polymer 
cobalt-chromium everolimus-eluting stent-EES (Xience/ 
Promus) (n=1618). The primary efficacy endpoint (target 
lesion revascularization-TLR at 1 year) occurred in 67 
patients (4.2%) in the BES group, and in 66 patients 
(4.2%) in the EES group, demonstrating noninferiority of 
BES over EES. Cumulative incidence of definite stent 
thrombosis was low and similar between the 2 groups 
(0.25% vs. 0.06%, p=NS). An angiographic substudy 
enrolling 528 patients (BES: n=263, and EES: n=265) 
demonstrated noninferiority of BES over EES regarding 
the primary angiographic endpoint of in-segment late loss 
(0.03+0.39 mm vs. 0.06+0.45 mm) at 266+43 days after 
stent implantation. The authors concluded that 1-year 
clinical and angiographic outcome after BES implantation 
was noninferior to and not different from that after EES 
implantation. Both BES and EES had a low rate of TLR 
and extremely low rate of stent thrombosis (Natsuaki et 
al, J Am Coll Cardiol 2013;62:181–190). 
 
ATLAS-ACS 2 TIMI 51: Reduction of Stent 
Thrombosis in Patients With Acute Coronary 
Syndromes (ACS) Treated With Rivaroxaban  
A total of 15,526 patients with recent ACS were 
randomized to receive either 2.5 mg or 5 mg bid of 
rivaroxaban or placebo for a mean of 13 months and up to 
31 months. Among patients who had a stent placed before 
or at the time of the event (n=9,631 or 63%), rivaroxaban 
significantly reduced definite and probable stent 
thrombosis in the pooled (1.9% vs 1.5%; hazard ratio -
HR: 0.65; p=0.017) and the 2.5 mg bid (1.9% vs 1.5%; 
HR: 0.61; p=0.023) treatment groups when compared 
with placebo, with a trend toward a reduction in the 5 mg 
bid group (1.9% vs. 1.5%; HR: 0.70; p = 0.089). Among 
patients who received dual antiplatelet therapy (DAPT) 
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with both aspirin and a thienopyridine, the benefit of 
rivaroxaban emerged during the period of active 
treatment with DAPT (HR: 0.68; combined rivaroxaban 
group vs. placebo). Among stented patients treated with 
DAPT, there was a mortality reduction among those 
treated with rivaroxaban 2.5 mg bid (HR: 0.56; p=0.014), 
but not with the 5 mg bid dose. The authors concluded 
that among stented patients with ACS treated with DAPT, 
administration of rivaroxaban 2.5 mg bid was associated 
with a reduction in stent thrombosis and mortality 
(Gibson et al, J Am Coll Cardiol 2013;62:286–290).  
 
PLATO Trial: Ticagrelor Compared With 
Clopidogrel Reduces the Incidence of Stent 
Thrombosis in Acute Coronary Syndromes Patients 
Of 18 624 patients hospitalized for acute coronary 
syndromes (ACS), 11289 (61%) had >1 intracoronary 
stent. Ticagrelor reduced stent thrombosis compared with 
clopidogrel across all definitions: definite, 1.37% (n=71) 
vs 1.93% (n=105; hazard ratio-HR, 0.67; P=0.009); 
definite or probable, 2.21% (n=118) vs 2.87% (n=157; 
HR, 0.75; P=0.017); and definite, probable, and possible, 
2.94% (n=154) vs 3.77 (n=201; HR, 0.77). The reduction 
in definite stent thrombosis was consistent regardless of 
ACS type, presence of diabetes mellitus, stent type, 
CYP2C19 genetic status, loading dose of aspirin, dose of 
clopidogrel, and use of glycoprotein IIb/IIIa inhibitors. 
The reduction in stent thrombosis with ticagrelor was 
greater for late (>30 days; HR, 0.48) and subacute (4 
hours–30 days; HR, 0.60) compared with acute (<24 
hours; HR, 0.94) stent thrombosis or for patients 
compliant to therapy compared with less compliant 
patients. Randomization to ticagrelor was a strong 
independent inverse predictor of definite stent thrombosis 
(HR, 0.65). The authors concluded that ticagrelor 
compared with clopidogrel reduces stent thrombosis in 
patients with ACS, with consistent benefit across a broad 
range of patient, stent, and treatment characteristics (Steg 
et al, Circulation 2013;128:1055-1065). 
 
GENERATIONS Trial: Prasugrel 5 mg in the Elderly 
Despite Lower Platelet Inhibition Maintains Non-
inferiority to Prasugrel 10 mg in Nonelderly Patients  
Prasugrel 5 mg in the elderly (>75 years, n=73; aged 
79+3 years) met the primary pharmacodynamic non-
inferiority criterion vs prasugrel 10 mg in non-elderly 
(>45 to <65 years; n=82; aged 56+5 years) stable 
coronary artery disease (CAD) patients receiving 
background aspirin. For prasugrel 5 mg, maximum 
platelet aggregation (MPA) was significantly lower (57 + 
14%) than clopidogrel (63 + 14%; p < 0.001) in elderly 
but higher than prasugrel 10 mg in non-elederly (46+ 
12%; p <0.001). Pharmacodynamic response by 3 
different assays during all treatments appeared similar 
between age cohorts. Prasugrel 5 mg resulted in fewer 
elderly poor responders than clopidogrel. Rates of mild 
bleeding were higher with prasugrel 10 mg but similar for 
prasugrel 5 mg vs clopidogrel 75 mg. The authors 
concluded that in aspirin-treated stable CAD patients, 
prasugrel 5 mg in the elderly had lower platelet inhibition 
but met the noninferiority criterion vs prasugrel 10 mg in 
no-elderly, with significantly better pharmacodynamic 
response and fewer poor responders compared to 
clopidogrel 75 mg in the elderly (Erlinge et al, J Am Coll 
Cardiol 2013;62:577–583).  
 
Continuous Positive Airway Pressure (CPAP) 
Therapy of Obstructive Sleep Apnea Reduces Atrial 
Fibrillation (AF) Recurrences After Catheter Ablation 
Among 62 patients with obstructive sleep apnea 
(OSA) out of 426 patients with AF undergoing 
pulmonary vein isolation (PVI), 32 were “CPAP users” 
and 30 “CPAP nonusers.” CPAP therapy resulted in 
higher AF-free survival rate (72% vs. 37%; p = 0.01) and 
AF-free survival off antiarrhythmic drugs or repeat 
ablation following PVI (66% vs. 33%; p = 0.02). AF 
recurrence rate of CPAP-treated patients was similar to a 
group of patients without OSA (HR: 0.7, p = 0.46). AF 
recurrence following PVI in CPAP nonuser patients was 
significantly higher (HR: 2.4, p < 0.02) and similar to that 
of OSA patients managed medically without ablation 
(HR: 2.1, p=NS). The authors concluded that CPAP is an 
important therapy in OSA patients undergoing PVI that 
improves arrhythmia free survival, while PVI offers 
limited value to OSA patients not treated with CPAP 
(Fein et a, J Am Coll Cardiol 2013; 62:300–305).  
 
Obstructive Sleep Apnea: a Novel Risk Factor for 
Sudden Cardiac Death?  
During a 5-year follow-up of 10,701 consecutive 
adults undergoing polysomnography for obstructive sleep 
apnea (OSA), 142 patients had sudden cardiac death 
(SCD) (annual rate 0.27%). In multivariate analysis, 
independent risk factors for SCD were age, hypertension, 
coronary artery disease, cardiomyopathy or heart failure, 
ventricular ectopy or nonsustained ventricular tachy-
cardia, and lowest nocturnal O2sat (per 10% decrease, 
hazard ratio-HR: 1.14; p=0.029). SCD was best predicted 
by age >60 years (HR: 5.53), apnea-hypopnea index >20 
(HR: 1.60), mean nocturnal O2sat <93% (HR: 2.93), and 
lowest nocturnal O2sat <78% (HR: 2.60; all p < 0.0001). 
The authors conclude that among adults referred for 
polysomnography, OSA predicted incident SCD. 
Nocturnal hypoxemia strongly predicted SCD 
independently of well-established risk factors. These 
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findings implicate OSA as a novel risk factor for SCD 
(Gami et al, J Am Coll Cardiol 2013;62:610–616).  
 
Air Pollution is an Acute Trigger of Atrial Fibrillation 
Among 300 eligible patients out of 1143 screened, 200 
with dual-chamber implantable cardioverter defibrillator 
(ICD) devices were enrolled and 176 were followed for at 
least 90 days. The association of AF onset with air quality 
including ambient particulate matter <2.5 mm 
aerodynamic diameter (PM2.5), black carbon, sulfate, 
particle number, NO2, SO2, and O3 in the 24 h prior to the 
arrhythmia was examined utilizing a case-crossover 
analysis. Of 176 patients followed for an average of 1.9 
years, 49 patients had 328 episodes of AF lasting >30 s. 
Positive but nonsignificant associations were found for 
PM2.5 in the prior 24 h, but stronger associations were 
found with shorter exposure windows. The odds of AF 
increased by 26% for each 6.0 mg/m3 increase in PM2.5 in 
the 2 h prior to the event (p=0.004). The authors 
concluded that particulate matter was associated with 
increased odds of AF onset within hours following 
exposure in patients with known cardiac disease, 
indicating that acute exposure to air pollution triggers AF 
(Link et al, J Am Coll Cardiol 2013;62:816–825).  
 
Community Study: Patients With Heart Failure are at 
Increased Risk of Cancer  
A case-control community study compared patients 
newly diagnosed with heart failure (HF) and age-, sex-, 
and date-matched controls without HF (961 pairs); also 
patients and individuals without cancer at the index date 
(596 pairs) were followed for development of cancer. 
Before the index date, 22% of HF cases and 23% of 
controls had a history of cancer (odds ratio - OR: 0.94). 
During 9,203 person-years of follow-up (7.7 + 6.4 years), 
244 new cancer cases were identified; HF patients had a 
68% higher adjusted risk of developing cancer (hazard 
ratio - HR: 1.68). The HRs were similar for men and 
women, with a trend toward a stronger association among 
subjects <75 years of age (p = 0.22) and during the most 
recent time period (p = 0.075). Among HF cases, incident 
cancer increased the adjusted risk of death (HR: 1.56). 
The authors concluded that HF patients are at increased 
risk of cancer, which appears to have increased over time, 
while cancer further increases mortality in HF patients 
(Hasin et al, J Am Coll Cardiol 2013;62:881–886).  
 
RE-LY: Integrating Ischemic and Bleeding Events as 
“Ischemic Stroke Equivalents” Indicates Similar 
Benefits of the 2 Doses of Dabigatran Over Warfarin 
In patients with AF, although the higher dose (150 mg 
bid) of dabigatran reduces ischemic stroke and increases 
bleeding compared with the lower dose (110 mg bid), the 
2 doses confer similar mortality. Ischemic and bleeding 
events were integrated as “ischemic stroke equivalents” 
in an analysis of the 18,113 AF patients in the RE-LY 
trial, in order to compare a weighted benefit of the 2 
doses of dabigatran with each other, and with that of 
warfarin. The analysis indicated that, compared with 
warfarin, there was a significant decrease in ischemic 
stroke equivalents with both dabigatran doses: –0.92 per 
100 patient years (p = 0.02) with dabigatran 110 mg bid 
and –1.08 (p = 0.01) with dabigatran 150 mg bid, while 
there was no difference between the 2 doses. The authors 
concluded that both doses of dabigatran as compared with 
warfarin have similar benefits when considering a 
weighted estimate of efficacy and safety, supporting the 
individualization of the dose based on patient 
characteristics and physician and patient preferences 
(Eikelboom et al, J Am Coll Cardiol 2013;62:900–908).  
 
Triple Antithrombotic Therapy May be Replaced by 
Oral Anticoagulant + Clopidogrel Without Additional 
Thrombotic Risk and With a Lower Risk of Bleeding  
Among 12,165 AF patients hospitalized with 
myocardial infarction (MI) and/or undergoing PCI, within 
1 year, MI or coronary death occurred in 2,255 patients 
(18.5%), ischemic stroke in 680 (5.6%), and bleeding 
events in 769 (6.3%). Compared to triple therapy (oral 
anticoagulant-OAC +aspirin +clopidogrel), no increased 
risk of recurrent coronary events was seen for dual 
therapy (OAC +clopidogrel: hazard ratio-HR: 0.69; OAC 
+ aspirin: HR: 0.96; or aspirin + clopidogrel: HR: 1.17), 
but aspirin plus clopidogrel was associated with a higher 
risk of ischemic stroke (HR: 1.50). Also, OAC + aspirin 
(HR: 1.52) and aspirin +clopidogrel (HR: 1.60) were 
associated with a significantly increased risk of all-cause 
death. When compared to triple therapy, bleeding risk 
was nonsignificantly lower for OAC + clopidogrel (HR: 
0.78) and significantly lower for OAC + aspirin and 
aspirin + clopidogrel. The authors concluded that AF 
patients with indication for triple antithrombotic therapy 
after MI/PCI, OAC and clopidogrel may be equal or 
better on both benefit and safety issues compared to triple 
therapy (Lamberts et al, J Am Coll Cardiol 2013;62:981–989).  
 
Left Atrial Pouch Thrombus Mimics Myxoma  
A 70-year-old woman with chronic atrial fibrillation 
underwent echocardiography which showed a large ovoid 
mass attached to the interatrial septum in the left atrium; 
the mass was further characterized by transesophageal 
echocardiography and was diagnosed as a myxoma. She 
was placed on anticoagulant therapy with warfarin before 
elective cardiac surgery and had no thromboembolic 
event during a 2.5-month period. Preoperative 
transesophageal echo showed the disappearance of the 
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intracardiac mass and the presence of a left atrial septal 
pouch, suggesting that the mass was a thrombus 
originating from the left atrial septal pouch (Shimamoto K 
et al, J Clin Ultrasound 2013 Aug 27. doi: 10.1002/jcu.22087).  
 
Malignant Bileaflet Mitral Valve Prolapse Syndrome 
Among 24 victims of idiopathic out-of-hospital 
cardiac arrest (i.e., no ischemia, cardiomyopathy, or 
channelopathy) having an implantable cardioverter 
defibrillator (ICD) (16 women, median age 33.5 years), 
bileaflet mitral valve prolapse (MVP) was found in 10 
(42%). Compared with patients with normal mitral 
valves, patients with bileaflet MVP were predominantly 
women (9 of 10 or 90% vs. 7 of 14 or 50%, p = 0.04); 
had a higher prevalence of biphasic or inverted T waves 
(7 of 9 or 78% vs. 4 of 14 or 29%, p =0.04); and on 
Holter monitoring had more frequent ventricular ectopy 
(ventricular bigeminy 100% vs 10%, p<0.0001; 
ventricular tachycardia 78% vs 10%, p=0.006, and 
premature ventricular contractions - PVCs originating 
from the outflow tract alternating with the papillary 
muscle or fascicular region 78% vs 20%, p=0.02). Over a 
median 1.8 years, 13 of 24 patients (54%) received 
appropriate ICD shocks. Only bileaflet MVP was 
associated with ventricular fibrillation recurrences 
requiring ICD therapy on follow-up (odds ratio: 7.2; p = 
0.028). The authors concluded that a “malignant” subset 
of patients with MVP may experience life-threatening 
ventricular arrhythmias and is characterized by bileaflet 
MVP, female sex, and frequent complex ventricular 
ectopic activity, including PVCs of the outflow tract 
alternating with papillary muscle or fascicular origin 
(Sriram et al, J Am Coll Cardiol 2013;62:222–230).  
 
“Low-Adenosine Syncope”: a Distinct Entity With 
Recent Sudden Onset in Middle/Old Age (>40 Years) 
Without Prodromes, Normal Heart and Normal ECG 
A group of 15 patients with sudden-onset syncope 
without prodromes with normal heart and normal ECG 
were compared with 31 patients with established 
vasovagal syncope (VVS). Patients in the study group 
were older than those with VVS (age 61+12 vs 46+ 17 
years) and had a history of fewer episodes of syncope 
(median of 2 vs 9 years) that were of more recent onset 
(median of 1 vs 10.5 years). The study group had lower 
median baseline adenosine plasma levels than the VVS 
group (0.25 vs 0.85 mmol/l). Adenosine plasma level of 
<0.36 best discriminated between groups, displaying 73% 
sensitivity and 93% specificity. Tilt table testing was 
more frequently positive in patients with VVS than in the 
study group (74% vs. 33%), with a similarly high 
positivity rate of adenosine/ATP testing in both groups 
(33-60% vs 37-43%). The authors concluded that clinical 
features and a low adenosine level define a distinct type 
of syncope, different from VVS, and suggest a causal role 
of the adenosine pathway (Deharo et al, J Am Coll 
Cardiol 2013;62:1075–1080). 
 
EnligHTN I: A New Multi-Electrode Ablation 
Catheter is Effective for Renal Denervation 
A novel multi-electrode system (EnligHTN™) was 
employed for catheter-based renal artery denervation in 
46 patients (67% male, mean age 60 years, and mean 
baseline office blood pressure 176/96 mmHg) with drug-
resistant hypertension. Office blood pressure was 
significantly reduced from baseline to 1, 3, and 6 months 
by 228/10, 227/10 and 226/10 mmHg, respectively (P < 
0.0001). No acute renal artery injury or other serious 
vascular complications occurred, with small, non-
relevant, changes in average estimated glomerular 
filtration rate. The authors concluded that renal 
sympathetic denervation, using the new catheter resulted 
in a rapid and significant office blood pressure reduction 
that was sustained through 6 months (Worthley et al, Eur 
Heart J 2013; 34: 2132–2140).  
 
Pulmonary Artery Denervation (PADN): a First-in-
Man Application to Treat Idiopathic Pulmonary 
Artery Hypertension (IPAH) / Feasible and 
Efficacious at Short-Term Follow-up  
Of 21 patients with IPAH, 13 underwent the PADN 
procedure and were compared with the other 8 who 
refused (control group). PADN was performed at the 
bifurcation of the main pulmonary artery (PA), and at the 
ostial right & left PA. At 3 months, PADN patients 
showed significant reduction of mean PA pressure (from 
55+5 mmHg to 36+5 mmHg, p<0.01), and improvement 
of the 6-min walk test (from 324+ 21 m to 491+38 m, p < 
0.006) and of the tricuspid excursion (Tei) index (from 
0.7+0.04 to 0.50+0.04, p<0.001). The authors concluded 
that PADN had a beneficial effect on functional capacity 
and hemodynamics in patients with drug-refractory IPAH 
(Chen et al, J Am Coll Cardiol 2013;62:1092–100).  
 
FinCV Study: High Thromboembolic Risk After 
Cardioversion of Acute Atrial Fibrillation (AF) in 
Patients with Conventional Risk Factors  
There were 38 (0.7%) definite thromboembolic events 
(31 strokes) and 4 TIAs within 30 days (median 2 days) 
after 5,116 successful cardioversions (CV) in 2,481 
patients with AF lasting <48 h who received neither oral 
anticoagulation nor peri-procedural heparin therapy. Age 
(odds ratio-OR: 1.05), female sex (OR: 2.1), heart failure 
(OR: 2.9), and diabetes (OR: 2.3) were the independent 
predictors of definite embolic events. The highest risk of 
thromboembolism (9.8%) was observed among patients 
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with heart failure and diabetes, whereas patients with no 
heart failure and age <60 years had the lowest risk of 
thromboembolism (0.2%). The authors concluded that the 
post-CV thromboembolic complications were increased 
in certain subgroups of patients when no anticoagulation 
is used after CV of acute AF (Airaksinen et al, J Am Coll 
Cardiol 2013;62:1187–1192). 
 
Residual SYNTAX Score: a Powerful Predictor of 5-
Year Mortality in the SYNTAX Trial 
In the PCI group of the SYNTAX Trial (n=903), 5-
year clinical outcomes were stratified by complete (CR) 
(residual SYNTAX Score 0) and incomplete revasculari-
zation (ICR) (residual SYNTAX Score >0). The mean 
baseline SYNTAX Score was 28.4±11.5 and residual 
SYNTAX Score was 4.5±6.9. A progressively higher 
residual SYNTAX Score (CR 0, n=386, 42.7%; ICR >0-
4, n=184, 20.4%; ICR >4-8, n=167, 18.5%; ICR>8, 
n=153, 16.9%) was shown to be a marker of increasing 
clinical comorbidity and anatomic complexity. Subjects 
with CR or residual SYNTAX Scores ≤8 had comparable 
5-year mortality (CR, 8.5%; residual SYNTAX Score 
>0–4, 8.7%; >4–8, 11.4%; P=0.60). A residual SYNTAX 
Score >8 was associated with 35% all-cause mortality at 
5-years (P<0.001). Similar results were obtained from the 
analysis of the medically treated diabetic and left main 
subgroups. The authors concluded that residual SYNTAX 
Score was a powerful indicator of 5-year mortality by 
determining the completeness of revascularization 
(Farooq et al, Circulation 2013;128:141-151). 
 
RELY-ABLE: a Higher Rate of Major Bleeding With 
the Higher Dabigatran Dose 
A total of 5851 patients (48%) enrolled in the RE-LY 
trial continued to receive dabigatran for up to 28 months 
after RE-LY (median follow-up, 2.3 years). Rates of 
stroke or systemic embolism were 1.46% and 1.60%/y on 
dabigatran 150 and 110 mg bid, respectively (hazard ratio 
- HR, 0.91). Rates of major hemorrhage were 3.74% and 
2.99%/y on dabigatran 150 & 110 mg (HR, 1.26). Rates 
of death were 3% & 3.1%/y (HR, 0.97). Rates of 
hemorrhagic stroke were 0.13% & 0.14%/y. The authors 
concluded that during 2.3 years of continued treatment 
with dabigatran after RE-LY, there was a higher rate of 
major bleeding with dabigatran 150 mg bid in comparison 
with 110 mg, and similar rates of stroke and death 
(Connolly et al, Circulation 2013;128:237–243).  
 
ARISTOTLE Secondary Analysis: Stroke, Mortality, 
& Major Bleeding Risks are Lower With Apixaban 
than Warfarin Regardless of AF Type and Duration 
A secondary analysis of the ARISTOTLE trial which 
included 18201 patients with atrial fibrillation (AF) (2786 
or 15.3% paroxysmal and 15412 or 84.7% persistent or 
permanent) comparing apixaban with warfarin indicated a 
consistent reduction in stroke or systemic embolism (P 
for interaction = 0.71), all-cause mortality (P for 
interaction = 0.75), and major bleeding (P for interaction 
= 0.50) with apixaban compared with warfarin for both 
AF types. Rate of stroke or systemic embolism was 
significantly higher in patients with persistent or 
permanent AF than patients with paroxysmal AF (1.52 vs. 
0.98%; P = 0.003, adjusted P = 0.015) with a trend 
towards higher mortality in patients with persistent or 
permanent AF (3.90 vs. 2.81%; P = 0.0002, adjusted P = 
0.066). The authors concluded that the risks of stroke, 
mortality, and major bleeding were lower with apixaban 
than warfarin regardless of AF type and duration (Al-
Khatib et al, Eur Heart J 2013; 34: 2464–2471).  
 
Atrial Fibrillation (AF) Epidemic: Prevalence of 8.8 
Million Adults >55 Years in 2010 in the European 
Union Estimated to Double by 2060 to 17.9 Million 
According to estimates from the Rotterdam Study and 
projections from the European Union’s statistics office, 
prevalence of AF for the group 55–59 years was 1.3% in 
men and 1.7% in women and increased to 24.2% in men, 
and 16.1% in women, for ages >85 years. Furthermore, it 
is estimated that in the European Union, 8.8 million 
adults over 55 years had AF in 2010 and projected that 
this number will double by 2060 to 17.9 million. The 
authors conclude that from 2010 to 2060, the number of 
adults >55 years with AF in the European Union will 
more than double with major public health implications 
(Krijthe et al, Eur Heart J 2013; 34: 2746–2751).  
 
Totally Subcutaneous ICD: a Viable Alternative to 
Conventional ICD? 
A subcutaneous implantable cardioverter defibrillator 
(ICD) was successfully implanted in 314 of 321 patients 
in whom it was attempted (74% male, mean age 52±16 
years and mean left ventricular ejection fraction of 
36±16%; 13% had a previous transvenous ICD). The 
180-day system complication-free rate was 99%, and 
sensitivity analysis of the acute ventricular fibrillation 
conversion rate was >90% in the entire group. Over a 
mean of 11 months, there were 38 discrete spontaneous 
episodes of ventricular tachycardia/ ventricular 
fibrillation recorded in 21 patients (6.7%), all of which 
successfully converted. A total of 41 patients (13.1%) 
received an inappropriate shock. The authors concluded 
that these findings support the efficacy and safety of the 
subcutaneous ICD System for the treatment of life-
threatening ventricular arrhythmias (Weiss et al, 
Circulation 2013;128:944-953).  
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Brugada Syndrome Behind Complete RBBB 
A group of 11 patients with no structural heart disease 
who had Brugada syndrome (BS) and complete right 
bundle branch block (CRBBB) were studied. In 7 
patients, BS was diagnosed before the development of 
CRBBB. BS was diagnosed upon spontaneous resolution 
of CRBBB (n=1) or by right ventricular pacing (n=3). On 
repeated ECGs, new additional upward-convex ST-
segment elevation was found in V2 or V3 in 3 patients. In 
2 patients, new ST-segment elevation was induced by 
class IC drugs. The QRS duration was more prolonged in 
patients with BS and CRBBB compared with age- and 
sex-matched controls: 170±13 vs 145±15 ms in V1 and 
144±19 vs 128±7 ms in V5 (both P<0.0001). The 
amplitude of R in V1 was larger in BS patients than in the 
controls (P=0.03), but that of R′ was similar (P=0.056). 
The authors concluded that BS can coexist behind 
CRBBB, and CRBBB can completely mask BS. BS 
might be demonstrated by resolution of CRBBB or by 
spontaneous or drug-induced ST-segment elevation 
(Aizawa et al, Circulation 2013;128:1048-1054). 
 
Greatest Benefit from Cardiac Resynchronization 
Therapy (CRT): Patients with LBBB & QRS > 150 ms  
Among 24169 patients receiving CRT-D, 1-year and 
3-year mortality rates were 9.2% and 25.9%, respectively. 
Risk of 3-year mortality was lowest among patients with 
LBBB and QRS duration of >150 ms (21%), compared 
with LBBB and QRS duration of 120-149 ms (26.5%; 
hazard ratio - HR, 1.30), no LBBB and QRS >150 ms 
(~31%; HR, 1.34), and no LBBB and QRS of 120-149 ms 
(32%; HR, 1.52). Risk of 1-year all-cause readmission 
was also lowest among patients with LBBB and QRS 
>150 ms (~39%), compared with LBBB and QRS of 120-
149 ms (45%; HR, 1.18), no LBBB and QRS >150 ms 
(~46%; HR, 1.16), and no LBBB and QRS of 120-149 ms 
(49.6%; HR, 1.31). There were no observed associations 
with complications. The authors concluded that LBBB 
and QRS >150 ms, compared with LBBB and QRS <150 
ms or no LBBB regardless of QRS duration, was 
associated with lower risk of all-cause mortality and of 
all-cause, cardiovascular, and heart failure readmissions 
(Peterson et al, JAMA 2013;310:617-626).  
 
REVERSE Study: Beneficial Effects of Cardiac 
Resynchronization Therapy (CRT) in Patients with 
Mild Heart Failure (HF) are Sustained Over 5 Years 
According to the 5-year results of the REVERSE 
study on CRT in 419 NYHA Class I-II HF patients with 
QRS ≥120 ms and left ventricular (LV) ejection fraction 
(LVEF) ≤40%, maximal improvement in function and LV 
remodeling were achieved at 2 years, with an increase of 
the 6-min walk test by mean of 18 m and quality of life 
by 8 units. There was a mean decrease in LV end-systolic 
volume index by ~23 mL/m2 and in end-diastolic volume 
index by 25 mL/m2; the mean increase in LVEF was 6% 
(P < 0.0001) with sustained improvement thereafter. The 
annual and 5-year mortality was 2.9 and 13.5% and the 
annual and 5-year rate of death or first HF hospitalization 
6.4, and 28%. The 5-year LV lead-related complication 
rate was 12.5%. The authors concluded that in patients 
with mild HF, CRT produced reverse LV remodelling 
and very low mortality and need for heart failure 
hospitalization. These effects were sustained over 5 years 
(Linde et al, Eur Heart J 2013; 34: 2592–2599).  
 
CHANCE: Clopidogrel plus Aspirin is Superior to 
Aspirin Alone for Secondary Prevention in Minor 
Stroke or TIA Without Further Hemorrhagic Risk 
A total of 5170 patients within 24 hours after the onset 
of minor ischemic stroke or high-risk transient ischemic 
attack (TIA) were assigned to combination therapy with 
clopidogrel and aspirin (clopidogrel initially 300 mg, 
followed by 75 mg qd for 90 days, plus aspirin at a dose 
of 75 mg qd for the first 21 days) or to placebo plus 
aspirin (75 mg qd for 90 days). Stroke recurred in 8.2% 
of patients in the clopidogrel–aspirin group, as compared 
with 11.7% of those in the aspirin group (hazard ratio, 
0.68; P<0.001). Hemorrhage developed in 7 patients 
(0.3%) in the clopidogrel–aspirin group and in 8 (0.3%) 
in the aspirin group (P=NS); the rate of hemorrhagic 
stroke was 0.3% in each group. The authors concluded 
that in patients with TIA or minor stroke treated within 24 
hours, the combination of clopidogrel and aspirin is 
superior to aspirin alone for reducing the risk of stroke in 
the first 90 days and does not increase the risk of 
hemorrhage (Wang et al, N Engl J Med 2013;369:11-19).  
 
ACCOAST: Pretreatment With Prasugrel has no 
Effect on Ischemic Events But Increases Major 
Bleeding  
A total of 4033 patients with non-ST elevation acute 
coronary syndromes (ACS) received prasugrel (30-mg 
loading dose) before coronary angiography (pretreatment 
group) or placebo (control group), with an additional 30 
mg of prasugrel given in the pretreatment group and 60 
mg in the control group at time of PCI. The rate of the 
primary efficacy end point (death, myocardial infarction, 
stroke, urgent revascularization, or glycoprotein IIb/IIIa 
inhibitor rescue therapy) through day 7, did not differ 
significantly between the two groups. The rate of the key 
safety end point of all major bleeding episodes, whether 
related or not related to coronary-artery bypass grafting 
(CABG), through day 7 was increased with pretreatment 
(hazard ratio, 1.90; P=0.006). The authors concluded that 
among patients with ACS who were scheduled to undergo 
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catheterization, pretreatment with prasugrel did not 
reduce the rate of major ischemic events up to 30 days 
but increased the rate of major bleeding complications 
(Montalescot et al, N Engl J Med 2013; 369:999-1010).  
 
PRAMI: Dilating NonCulprit Lesions in Acute 
Myocardial Infarction Confers Significant Benefit 
(Preventive Angioplasty) 
A total of 465 patients with ST elevation myocardial 
infarction (STEMI), undergoing primary angioplasty 
(PCI) of the infarct-related artery (2008-2013), were 
randomly assigned to either preventive PCI (234 patients) 
or no preventive PCI (231 patients). Over a mean of 23 
months, the primary outcome (cardiac death, nonfatal 
myocardial infarction, or refractory angina) occurred in 
21 patients in the preventive PCI group and in 53 patients 
in the control group (infarct-artery-only PCI) (overall 
hazard ratio-HR, 0.35; P<0.001 / HR 0.34 for cardiac 
death, 0.32 for nonfatal myocardial infarction, and 0.35 
for refractory angina). The authors concluded that in 
patients with STEMI and multivessel coronary artery 
disease undergoing infarct-artery PCI, preventive PCI in 
noninfarct vessel stenoses significantly reduced the risk 
of adverse cardiovascular events, compared with PCI 
limited to the culprit lesion (Wald et al, N Engl J Med 
2013; 369:1115-1123).  
 
Combined Therapy With Vasopressin-Epinephrine + 
Methylprednisolone During CPR and Stress-Dose 
Hydrocortisone in Postresuscitation Shock Confers 
Improved Survival in Cardiac Arrest Victims 
Cardiac arrest victims (n=268) received either 
vasopressin plus epinephrine (VSE group, n = 130) or 
saline placebo plus epinephrine (control group, n = 138) 
for the first 5 CPR cycles after randomization, followed 
by additional epinephrine if needed. During the first CPR 
cycle after randomization, patients in the VSE group 
additionally received methylprednisolone (40 mg). Shock 
after resuscitation was treated with stress-dose 
hydrocortisone (300 mg daily for 7 days maximum and 
gradual taper) (VSE group, n = 76) or saline placebo 
(control group, n = 73). Patients in the VSE group vs 
patients in the control group had higher probability for 
return of spontaneous circulation (ROSC) of 20 min or 
longer (84% vs 66%; odds ratio-OR, 2.98; P =0 .005) and 
survival to hospital discharge (14% vs 5%; OR, 3.28; 
P =0 .02). Patients in the VSE group with post-
resuscitation shock vs respective patients in the control 
group had higher probability for survival to hospital 
discharge with adequate neurological function (21%] vs 
~8%; OR, 3.74; P =0 .02. Adverse events were similar in 
the 2 groups. The authors concluded that combined 
vasopressin-epinephrine and methylprednisolone during 
CPR and stress-dose hydrocortisone in postresuscitation 
shock resulted in improved survival to hospital discharge 
with favorable neurological status (Mentzelopoulos et al, 
JAMA 2013;310:270-279).  
 
MIDA Registry: Early Surgical Intervention is 
Superior to Watchful Waiting for Mitral 
Regurgitation Due to Flail Mitral Valve Leaflets 
Among 1021 patients with flail mitral valve 
regurgitation, 575 patients were initially medically 
managed and 446 underwent mitral valve surgery within 
3 months. There was no significant difference in early 
mortality (1.1% for early surgery vs 0.5% for medical 
management, P=NS) and new-onset heart failure rates 
(0.9% for early surgery vs 0.9% for medical management, 
P=NS) between treatment strategies at 3 months. In 
contrast, long-term survival rates were higher for patients 
with early surgery (86% vs 69% at 10 years, P <0 .001); 
5-year mortality was reduced by 52.6% (P <0 .001). 
Long-term heart failure risk was also lower with early 
surgery (7% vs 23% at 10 years, P <0 .001). Reduction in 
late-onset atrial fibrillation was not observed. The authors 
concluded that patients with mitral valve regurgitation 
due to flail mitral leaflets, performance of early mitral 
surgery compared with initial medical management was 
associated with greater long-term survival and a lower 
risk of heart failure, with no difference in new-onset atrial 
fibrillation (Suri et al, JAMA 2013;310:609-616).  
 
Important Review and Other Articles  
Genetics in channelopathies (Schwartz et al, J Am Coll 
Cardiol 2013;62:169-180), TAVI in Europe (Mylotte et al, J 
Am Coll Cardiol 2013;62:210-219), Renal denervation (Davis 
et al, J Am Coll Cardiol 2013;62:231-241), Heart failure with 
preserved ejection fraction (Paulus et al, J Am Coll Cardiol 
2013;62:263-271), ACCF/AHA/SCAI 2013 Update of the 
Clinical Competence Statement on Coronary Artery 
Interventional Procedures (Harold et al, J Am Coll Cardiol 
2013;62:357–396), Obstructive sleep apnea (Drager et al, J Am 
Coll Cardiol 2013;62:569–576), Early repolarization (Adler et 
al, J Am Coll Cardiol 2013;62:863-868), ICD use (Hohnloser 
& Israel Circulation 2013; 128:172-183), Cognitive function 
after CABG (Hogan et al, Circulation 2013; 128:162-171), 
Cardiovascular function and treatment in β-thalassemia major 
(Pennell et al, Circulation 2013; 128:281-308), Device 
infections (Mulpuru et al, Circulation 2013;128:1031-1038), 
Acute aortic syndrome (Sheikh et al, Circulation 2013; 
128:1122-1127), ARVC (Saguner et al, Circulation 
2013;128:1381-1386), Telemedicine & cardiac implants 
(Varma & Ricci, Eur Heart J 2013;34:1885-1893), Practical 
guide on use of new oral anticoagulants (Heidbuchel et al, Eur 
Heart J 2013;34:2094-2106), Catheter based renal denervation 
(Mahfoud et al, Eur Heart J 2013;34:2149-2157), 2013 
ESH/ESC Guidelines for the management of arterial 
hypertension (Mancia et al, Eur Heart J 2013;34:2159-2219), 
68 
 
2013 ESC Guidelines on cardiac pacing and cardiac 
resynchronization therapy (Brignole et al, Eur Heart J 
2013;34:2281-2329), Diabetes & vascular disease (Paneni et al, 
Eur Heart J 2013;34:2436-2443 / Beckman et al, Eur Heart J 
2013;34:2444-2452), Myocarditis (Caforio et al, Eur Heart J 
2013;34:2636-2648), Coronary collaterals (Seiler et al, Eur 
Heart J 2013;34:2674-2682), STEMI: adjunctive reperfusion 
strategy (Curzen et al, Lancet 2013; 382:633-643) 
 
2013 European Society of Cardiology Congress News 
 
In a Hot Line session the results from the phase II RE-
ALIGN study were presented, indicating that the oral 
anticoagulant dabigatran failed to protect patients with 
mechanical valves from thromboembolic events. Rather, 
a higher number of thromboembolic and bleeding 
complications occurred in these patients compared to 
standard treatment with warfarin. This was the reason that 
prompted the early termination of this study after 
enrolment of 252 patients. The composite of stroke, TIA, 
systemic embolism, MI or death occurred in 15 patients 
(9%) in the dabigatran group and in 4 patients (5%) in the 
warfarin group. Major bleeding occurred in 7 patients 
(4%) on dabigatran and 2 (2%) on warfarin.  
 The factor Xa inhibitor edoxaban was found to be 
non-inferior to standard therapy with warfarin for the 
prevention of venous thromboembolism (VTE) in the 
Hokusai-VTE trial. The study included 4921 patients 
with deep vein thrombosis and 3319 patients with 
pulmonary embolism, who were randomized to 60 mg 
edoxaban daily (or 30 mg for those considered at higher 
risk of bleeding) or warfarin for 3-12 months. The 
primary end-point (recurrent symptomatic VTE) occurred 
in 3.2% of patients on edoxaban and 3.5% of patients on 
warfarin. In the subgroup with pulmonary embolism, 
recurrent events were reported in 3.3% on edoxaban and 
6.2% on warfarin. Bleeding occurred in 8.5% for 
edoxaban and 10.3% for warfarin.  
 The investigational anticoagulant otamixaban had 
increased rates of bleeding with no reduction noted in 
mortality or MI events in patients with non-ST elevation 
ACS, according with the results of the phase III TAO 
study. Another negative study was presented, the TASTE 
trial, whereby aspiration of thrombus prior to angioplasty 
and stenting in STEMI patients did not improve survival 
compared with primary PCI and stenting alone.  
 Patients with STEMI who have additional preventive 
angioplasty have significantly better outcomes than thos 
who only undergo to primary PCI of the infarct-artery, 
according to the PRAMI trial. STEMI patients after 
completion of infarct-artery PCI were randomized to 
either preventive (additional) PCI of other significant 
coronary stenosis (n=234) or no further PCI (n=231). At 
23 months, the primary outcome (cardiac death, non-fatal 
MI, or refractory angina) occurred in 21 patients assigned 
to preventive PCI and in 53 patients assigned to no 
preventive PCI, an absolute risk reduction of 14% and a 
relative risk reduction of 65% (hazard ratio 0.35).  
 According with the results of the ACCOAST trial, 
pretreatment with prasugrel in patients with non-ST 
elevation ACS was associated with an increased (almost 
double) risk of major bleeding (2.6% vs 1.4% at 7 days 
and 2.9% vs 1.5% at 30 days).  
 Two trials of oral anti-hyperglycemic agents, 
dipeptidyl peptidase 4 (DPP-4) inhibitors saxagliptin and 
alogliptin, were reported to meet the non-inferiority 
criterion for ischemic target. According to the results of 
the phase IV SAVOR-TIMI 450 (saxagliptin) and the 
EXAMINE (alogliptin) studies, diabetic patients 
receiving these drugs did not have any increase or 
decrease of major adverse cardiac events. In another 
negative trial, the ASSURE study, the apoA-1 inducer 
RVX-208 did not raise HDL levels and failed to promote 
atheromatous plaque regression. A rather neutral study 
(AQUARIUS) was also reported, which showed that the 
renin inhibitor, aliskiren, neither improves nor slows the 
progression of coronary atherosclerosis. Another phase II 
trial (ATOMIC-AHF) testing the cardiac myosin 
activator omecamtiv mecarbil in heart failure reported 
that the drug did not achieve its primary efficacy endpoint 
in reducing dyspnea in patients with acute heart failure.  
 An important study for cardiac resynchronization 
therapy (CRT), the Echo-CRT study, included 809 
patients with narrow QRS, NYHA class III-IV heart 
failure, left ventricular ejection fraction <35%, who were 
randomized 1:1 to CRT (n=404) or control (n=405) with 
the device turned off in the control group. At a mean 
follow-up of 19.4 months, the primary endpoint (death or 
first hospitalization for worsening heart failure) occurred 
in 28.7% of patients in the CRT group and 25.2% in the 
control group. In addition, 11.1% of CRT patients died vs 
6.4% in the control group, with cardiovascular mortality 
in 9.2% of CRT patients vs 4.2% in the control group. 
Thus, the conclusion was that CRT in patients with 
narrow QRS has no benefit and may even harm patients 
with heart failure, results which are quite similar with the 
recently reported findings of the LESSER EARTH study.  
 New ESC guidelines (2013) were reported: 
Guidelines for Cardiac Pacing & CRT, Guidelines on 
Diabetes & Cardiovascular Disease (in collaboration 
with the European Association for the Study of Diabetes-
EASD), Guidelines on Hypertension (developed with the 
European Society of Hypertension), & Guidelines on 
Stable Coronary Artery Disease 
(http://www.escardio.org/guidelines-surveys/esc-
guidelines/Pages/GuidelinesList.aspx).   
